Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06513585 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy

Study acronym: PA-SELECT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 15, 2025 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Phase: Not specified to Not applicable
    • Enrollment target: 500 to 570
    • Interventions: Superselective adrenal artery embolization or adrenalectomy (Procedure)
    • Study title shortened, about 4 words
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v3
  4. Secondary endpoints: details revised at 1 of 14 entries
    • Study title shortened, about 5 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study was to compare the efficacy and safety of adrenalectomy and superselective adrenal artery embolization in a prospective, multicenter, randomized controlled study. To provide a new interventional alternative therapy for primary aldosteronism.
Trial Details
NCT Number NCT06513585
Lead Sponsor Xinjiang Medical University
Collaborators: First Affiliated Hospital of Xinjiang Medical University
Conditions
(from sponsor)		 Primary Aldosteronism, Suprarenalectomy, Super Selective Adrenal Artery Embolization
Related terms Hyperaldosteronism
Enrollment 570 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov